Valuation dashboard for Ensysce Biosciences, Inc. (ENSC) with P/E N/A, P/B -7.69, EV/EBITDA 0.16 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose.
Analysis Summary
Trailing-twelve-month margins: gross margin 100.0%, operating margin -10.9%, net margin -10.8%.
At the current price of $0.45, ENSC has negative trailing earnings (P/E not meaningful) and an ROE of -316.63%. Market capitalisation stands at $7M.
Balance sheet quality for ENSC: current ratio of 1.6. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | -7.69 |
| EV / EBITDA | 0.16 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ENSC | Ensysce Biosciences, Inc. | $7M | -316.6% | ||
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $0.45 |
| Market Cap | $7M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -316.63% |
| Return on Invested Capital | -320.89% |
| Return on Assets | -136.54% |
| Gross Margin | 100.00% |
| Operating Margin | -1087.47% |
| Net Margin | -1084.23% |
Related companies: AIM · CANF · KALA · KZIA · OGEN · QLGN · SNGX
Explore sector: Healthcare · Biotechnology
More sections of ENSC: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks